Answers are grounded in this paper and cite their sources.
Despite evidence supporting primary PCI for STEMI, significant gaps remain in its timely delivery and utilization in the United States, highlighting the need for regionalized care systems.
he overwhelming enthusiasm for primary percutaneous coronary intervention (PCI) as the preferred reperfusion strategy for patients with ST-segment elevation myocardial infarction (STEMI) is fueled by evidence from randomized trials suggesting that PCI is superior to fibrinolytic therapy alone in reducing the rates of death, reinfarction, intracranial bleeding, reocclusion of the infarct artery, and recurrent ischemia even if performed when transport to a hospital with PCI capability is required. 1,2In the United States, this enthusiasm is tempered by the reality that approximately one third of patients do not receive any reperfusion therapy despite its availability and the absence of any contraindication, and that only a minority (18%) of patients with STEMI receive primary PCI. 3 Furthermore, of those patients treated with primary PCI, fewer than 40% undergo reperfusion of the infarct artery within 90 minutes after arrival to the initial hospital, 4 a goal advocated by the American College of Cardiology/American Heart Association guidelines. 5Of the nearly 5000 acute-care hospitals in this country, Ϸ2200 have catheterization laboratories.Among those, only 1200 are capable of performing PCI, which makes it challenging for several states to provide primary PCI to selected patients in a timely fashion. 6In fact, several regions are beginning to organize and monitor both transfer and triage protocols for patients with STEMI. 7,8
No takes yet. Share an insight, caveat, or question.
Alice K. Jacobs (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: